Mouse Monoclonal S100A2 Antibody

+ +

•  

   
     All lanes : Anti-S100A2 Antibody at 1:4000 dilution Lane 1: A431 whole cell lysate Lane 2: HACAT whole cell lysate Lane 3: SW480 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 11 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervical epithelial adenocarcinoma cell line) cells labeling S100A2 with P33515 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-mouse IgG   secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm and nucleus staining on HeLa cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin  at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).    

•  

   
     P33515 staining S100A2 in human skin tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

•  

   
     P33515 staining S100A2 in human lung tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

The S100A2 antibody is a tool used to detect S100A2. a calcium-binding protein belonging to the S100 family. S100A2 is encoded by the *S100A2* gene on human chromosome 1q21 and plays roles in cell cycle regulation, cytoskeleton dynamics, and intracellular signaling. While many S100 proteins are linked to cancer progression, S100A2 exhibits context-dependent behavior. In certain cancers (e.g., breast, lung, prostate), it may act as a tumor suppressor by promoting apoptosis or inhibiting proliferation. Conversely, in melanoma and pancreatic cancer, elevated S100A2 expression correlates with tumor aggressiveness and poor prognosis.

S100A2 antibodies, typically monoclonal or polyclonal, are employed in techniques like immunohistochemistry (IHC), Western blotting, and ELISA to study its expression patterns and subcellular localization. These studies help clarify its dual roles in tumorigenesis and metastasis. Recent research also explores its potential as a diagnostic or prognostic biomarker. For example, nuclear S100A2 in oral squamous cell carcinoma is associated with better survival, while cytoplasmic expression in renal cell carcinoma predicts worse outcomes.

Challenges include standardization of detection protocols and resolving discrepancies across studies. Additionally, S100A2’s interactions with p53. EGFR, and other signaling molecules are under investigation for therapeutic targeting. Despite unresolved questions, S100A2 antibodies remain critical for unraveling its complex roles in health and disease.